OPRL1

Nociceptin receptor · P41146 · OPRL1 on Sugi Atlas →

138,153 patent compounds predicted against OPRL1, 56,753 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL304093	0.75	19/20
SCHEMBL317530	1.00	18/20
SCHEMBL304322	0.72	18/20
SCHEMBL304094	0.53	18/20
SCHEMBL304095	0.53	18/20
SCHEMBL303247	0.63	17/20
SCHEMBL240013	0.62	16/20
Hydrochloric Acid (SCHEMBL302131)	0.61	16/20
SCHEMBL42581	0.52	16/20
Hydrochloric Acid (SCHEMBL302167)	0.70	15/20
SCHEMBL206791	0.62	15/20
Hydrochloric Acid (SCHEMBL303067)	0.52	15/20
SCHEMBL181682	1.00	14/20
SCHEMBL75647	0.71	14/20
Hydrochloric Acid (SCHEMBL62422)	0.69	14/20
SCHEMBL153569	0.59	14/20
SCHEMBL69083	0.56	14/20
Hydrochloric Acid (SCHEMBL302160)	0.53	14/20
Hydrochloric Acid (SCHEMBL301795)	0.66	13/20
SCHEMBL207976	0.60	13/20

Clinical trials — most relevant to OPRL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Colonic Motor Patterns in Healthy Volunteers	PHASE4	COMPLETED
Oliceridine in Patients With Acute Burn Injuries	PHASE4	COMPLETED
Effects of Tapentadol Versus Oxycodone After Hysterectomy.	PHASE4	COMPLETED
Treatment of Chronic Pain From Osteoarthritis	PHASE4	WITHDRAWN
Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use	PHASE4	UNKNOWN
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery	PHASE4	RECRUITING
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain	PHASE4	SUSPENDED
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery	PHASE4	NOT_YET_RECRUITING
Genetic Effects on Dopamine Response to an Opiate	PHASE2	COMPLETED
NP2 Enkephalin For Treatment of Intractable Cancer Pain	PHASE2	COMPLETED
The Analgesic Efficacy of Perineural Nalbuphine as an Adjuvant to Bupivacaine in Ultrasound Guided Superficial Cervical Plexus Nerve Block for Thyroid Surgeries. A Double Blinded Randomized Controlled Trial.	PHASE2	RECRUITING
Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain	PHASE2	COMPLETED
A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans	PHASE2	COMPLETED
Sublingual Dexmedetomidine for Treating Opioid Withdrawal	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects	PHASE1	COMPLETED
CRF - Nociceptin Receptor Interactions	EARLY_PHASE1	COMPLETED
Patient Controlled Analgesia Pharmacogenetic Study	nan	COMPLETED
Pharmacogenetic Morphine Spine Study	nan	COMPLETED
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Multicenter Perioperative Opioid Pharmacogenetic Study	nan	COMPLETED
Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction	nan	UNKNOWN
Endogenous Opioid Systems and Symptom Change in Fibromyalgia	nan	WITHDRAWN
Precision Medicine Guided Treatment for Cancer Pain	nan	COMPLETED
Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics	nan	RECRUITING
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use	nan	COMPLETED
A Study of Genetic Variation Influencing Pain and Response to Opioid Medications	nan	WITHDRAWN
Precision Medicine in Anesthesia	nan	WITHDRAWN
Cancer Pain Single Nucleotide Polymorphisms (SNPs)	nan	COMPLETED
Oral Ketamine as an Adjuvant to Opioids for Pain Treatment in Cancer Patients	nan	UNKNOWN
OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a OPRL1 binder may also engage these)

Protein	Name	Similarity
P35377	—	1.000	P35377 →
P79292	—	1.000	P79292 →
P35370	—	0.999	P35370 →
P47748	—	0.994	P47748 →
P33533	—	0.988	P33533 →
P32300	—	0.983	P32300 →
OPRD1	Delta-type opioid receptor	0.974	landscape →
P41144	—	0.970	P41144 →
OPRK1	Kappa-type opioid receptor	0.967	landscape →
Q2KIP6	—	0.967	Q2KIP6 →
P42866	—	0.966	P42866 →
P34975	—	0.965	P34975 →
P33534	—	0.964	P33534 →
P33535	—	0.959	P33535 →
F1MV99	—	0.957	F1MV99 →
Q95M54	—	0.957	Q95M54 →
OPRM1	Mu-type opioid receptor	0.957	landscape →
Q5IS39	—	0.957	Q5IS39 →
Q5IS84	—	0.956	Q5IS84 →
O08858	—	0.956	O08858 →
P30938	—	0.953	P30938 →
P79350	—	0.952	P79350 →
Q95247	—	0.950	Q95247 →
Q9MYW9	—	0.949	Q9MYW9 →
GALR1	Galanin receptor type 1	0.943	landscape →
P56479	—	0.942	P56479 →
Q49LX5	—	0.941	Q49LX5 →
CCKBR	Gastrin/cholecystokinin type B receptor	0.940	landscape →
SSTR1	Somatostatin receptor type 1	0.940	landscape →
Q62805	—	0.939	Q62805 →